FGF23 and disorders of phosphate homeostasis

Research output: Contribution to journalArticle

92 Scopus citations


It is well known that fibroblast growth factor (FGF) family members are associated with embryonic development and are critical for basic metabolic functions. This review will focus upon fibroblast growth factor-23 (FGF23) and its roles in disorders associated with phosphate handling. The discovery that mutations in FGF23 were responsible for the isolated renal phosphate wasting disorder autosomal dominant hypophosphatemic rickets (ADHR) has ascribed novel functions to the FGF family. FGF23 circulates in the bloodstream, and animal models demonstrate that FGF23 controls phosphate and Vitamin D homeostasis through the regulation of specific renal proteins. The ADHR mutations in FGF23 produce a protein species less susceptible to proteolytic processing. X-linked hypophosphatemic rickets (XLH), tumor-induced osteomalacia (TIO), and fibrous dysplasia of bone (FD) are disorders involving phosphate homeostasis that share phenotypes with ADHR, indicating that FGF23 may be a common denominator for the pathophysiology of these syndromes. Our understanding of FGF23 will help to develop novel therapies for phosphate wasting disorders, as well as for disorders of increased serum phosphate, such as tumoral calcinosis, a rare disorder, and renal failure, a common disorder.

Original languageEnglish (US)
Pages (from-to)221-232
Number of pages12
JournalCytokine and Growth Factor Reviews
Issue number2 SPEC. ISS.
StatePublished - Apr 2005


  • ADHR
  • FGF
  • FGF23
  • Fibrous dysplasia
  • Metabolic bone disease
  • Phosphate wasting
  • TIO
  • XLH

ASJC Scopus subject areas

  • Immunology
  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'FGF23 and disorders of phosphate homeostasis'. Together they form a unique fingerprint.

  • Cite this